Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications

Conditions: Diabetes Mellitus, Type 2
Interventions: Drug: Valsartan 160 mg + nateglinide 60 mg; Drug: Valsartan 160 mg + nateglinide placebo; Drug: Nateglinide 60 mg + valsartan placebo; Drug: Valsartan placebo + nateglinide placebo
Sponsors: Novartis Pharmaceuticals
Completed

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 9, 2023Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments